| Catalog No. | Size | Price (USD) |
| 203001-T08-50 | 50 µL | $147.96 |
| 203001-T08-100 | 100 µL | $251.64 |
| 203001-T08-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-Alkaline phosphatase/APLI Antibody, Rabbit Polyclonal |
| Validated applications | IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human Alkaline phosphatase/APLI |
| Immunogen | E. coli-derived Human intestinal alkaline phosphatase/ALPI fragment |
| Preparation | Produced in rabbits immunized with E. coli-derived Human intestinal alkaline phosphatase/ALPI fragment, and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | PBS, pH7.0 with 0.03% Proclin300 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-IAP Antibody
Image / Experimental Information
| Image 1 Description | Immunochemical staining of human ALPI in human placenta with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections. |
| Image 1 Alt Text | Human intestinal alkaline phosphatase Immunohistochemistry(IHC) 22216 |
| Image 1 URL | Source image |
Background Information
| Full Name | alkaline phosphatase, intestinal |
| Description | ALPI encodes for intestinal phosphatase alkaline, a brush border metalloenzyme that hydrolyses phosphate from the lipid A moiety of lipopolysaccharides and thereby drastically reduces Toll-like receptor 4 agonist activity. ALPI mutations impaired either stability or catalytic activity of ALPI and rendered it unable to detoxify lipopolysaccharide-dependent signalling. ALPI mutations should be included in screening for monogenic causes of inflammatory bowel diseases and lay the groundwork for ALPI-based treatments in intestinal inflammatory disorders. |
| Research Areas |
|
| References |
|
-HD12JL1713-100-human-placenta-IHC-P.png){kind=link}